Lite Strategy, Inc. (LITS)
1.04
+0.05
(+4.63%)
USD |
NASDAQ |
Sep 02, 16:00
1.04
0.00 (0.00%)
After-Hours: 20:00
Lite Strategy Research and Development Expense (TTM) : 0.169M for March 31, 2026
Research and Development Expense (TTM) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| March 31, 2026 | 0.169M |
| December 31, 2025 | 0.508M |
| September 30, 2025 | 0.77M |
| June 30, 2025 | 3.923M |
| March 31, 2025 | 7.784M |
| December 31, 2024 | 12.64M |
| September 30, 2024 | 16.24M |
| June 30, 2024 | 16.56M |
| March 31, 2024 | 15.19M |
| December 31, 2023 | 25.07M |
| September 30, 2023 | 36.47M |
| June 30, 2023 | 52.45M |
| March 31, 2023 | 71.72M |
| December 31, 2022 | 78.93M |
| September 30, 2022 | 85.15M |
| June 30, 2022 | 85.64M |
| March 31, 2022 | 80.10M |
| December 31, 2021 | 75.66M |
| September 30, 2021 | 76.36M |
| June 30, 2021 | 69.40M |
| March 31, 2021 | 60.96M |
| December 31, 2020 | 52.04M |
| September 30, 2020 | 38.10M |
| June 30, 2020 | 34.06M |
| March 31, 2020 | 34.24M |
| Date | Value |
|---|---|
| December 31, 2019 | 34.35M |
| September 30, 2019 | 35.13M |
| June 30, 2019 | 32.30M |
| March 31, 2019 | 28.73M |
| December 31, 2018 | 22.73M |
| September 30, 2018 | 17.10M |
| June 30, 2018 | 17.04M |
| March 31, 2018 | 14.65M |
| December 31, 2017 | 13.46M |
| September 30, 2017 | 11.66M |
| June 30, 2017 | 7.237M |
| March 31, 2017 | 9.149M |
| December 31, 2016 | 10.69M |
| September 30, 2016 | 12.23M |
| June 30, 2016 | 13.40M |
| March 31, 2016 | 13.20M |
| December 31, 2015 | 16.55M |
| September 30, 2015 | 20.07M |
| June 30, 2015 | 23.82M |
| March 31, 2015 | 26.46M |
| December 31, 2014 | 25.10M |
| September 30, 2014 | 22.79M |
| June 30, 2014 | 19.33M |
| March 31, 2014 | 14.57M |
| December 31, 2013 | 10.70M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (TTM) Benchmarks
| SELLAS Life Sciences Group, Inc. | 20.35M |
| ACADIA Pharmaceuticals, Inc. | 331.01M |
| Alnylam Pharmaceuticals, Inc. | 1.509B |
| Anika Therapeutics, Inc. | 27.45M |
| Savara, Inc. | 86.84M |